Αρχική World News Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in Patients... World News Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in Patients With Platinum-Resistant Recurrent Ovarian Cancer Από Ogkologos - 23 Απριλίου, 2026 367 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-ov65/KEYNOTE-B96 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Could A Diabetes Diagnosis Help Detect Pancreatic Cancer Early? 7 Ιουλίου, 2021 Grandma Saves Her Money To Put Up A Billboard For Everyone... 14 Ιουνίου, 2019 April is Occupational Therapy (OT) Month- What is OT and how... 8 Απριλίου, 2021 FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for... 28 Οκτωβρίου, 2026 Φόρτωση περισσοτέρων HOT NEWS Blind Man Overcomes Life Of Struggles & Becomes An Incredible Woodworker Time to get stratified FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive NSCLC Bowel scope screening to stop in England